Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient ...

Sol-Gel Technologies (SLGL) entered into a product purchase agreement with a subsidiary of Mayne Pharma Group (MAYNF) for the sale and ...

Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...

This innovative design promises batteries that can be charged in just 20 minutes and can endure over 1,500 charge cycles, ...

The sol-gel synthesis process begins with the preparation of a sol, where metal or metalloid precursors are dissolved in a solvent. These precursors undergo hydrolysis and polymerization reactions, ...

As the demand continues to grow for batteries capable of ultra-fast charging and high energy density in various sectors—from ...

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers ...

Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT ...